ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near New York, NY, USA:

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ...

Enrolling
Refractory Plasmablastic Lymphoma
Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
Drug: Belantamab Mafodotin

Phase 2

Jacob Soumerai, MD

New York, New York, United States and 2 other locations

a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma...

Active, not recruiting
Relapsed Follicular Lymphoma
Refractory Follicular Lymphoma
Drug: Venetoclax
Drug: Ibrutinib

Phase 1, Phase 2

Georgetown University
Georgetown University

Hackensack, New Jersey, United States and 2 other locations

combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment before. The investigators hypot...

Enrolling
Follicular Lymphoma
Drug: Mosunetuzumab
Drug: Tazemetostat Pill

Phase 2

Weill Cornell Medicine (WCM)
Weill Cornell Medicine (WCM)

New York, New York, United States

of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....

Enrolling
Hodgkin Lymphoma, Adult
Hodgkin Lymphoma
Drug: MT-601

Phase 1

Marker Therapeutics

New York, New York, United States and 6 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Hackensack, New Jersey, United States and 89 other locations

patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

New York, New York, United States and 7 other locations

DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research.Adults with non-Hodgkin lymphoma...

Active, not recruiting
Lymphoma, Malignant
Non-hodgkin Lymphoma
Drug: DS-3201b

Phase 1

Daiichi Sankyo
Daiichi Sankyo

New York, New York, United States and 20 other locations

and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary object...

Active, not recruiting
B Cell Lymphoma
Mantle Cell Lymphoma
Drug: Ibrutinib
Drug: Palbociclib

Phase 2

Alliance Foundation Trials

New York, New York, United States and 8 other locations

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have e...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: HMPL-523

Phase 1

HUTCHMED
HUTCHMED

New Hyde Park, New York, United States and 31 other locations

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL)....

Enrolling
T-cell Lymphoma
Cutaneous T-cell Lymphoma
Drug: Fenretinide

Phase 1

SciTech Development

New York, New York, United States and 5 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems